Achieve Life Sciences Q3 net loss widens

Reuters

11/06

<a href="https://laohu8.com/S/ACHV">Achieve Life</a> Sciences Q3 net loss widens

Overview

Achieve Q3 net loss and EPS missed analyst expectations
FDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026
Awarded FDA Commissioner's National Priority Voucher for vaping cessation

Outlook

Company confirms PDUFA action date for cytisinicline as June 20, 2026
Achieve awarded FDA Priority Voucher for vaping cessation
Company highlights unmet need in vaping cessation market

Result Drivers

Total operating expenses for the three and nine months ended September 30, 2025, were $14.7 million and $40.1 million, respectively

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Miss	-$0.28	-$0.26 (7 Analysts)
Q3 Net Income	Miss	-$14.44 mln	-$12.20 mln (7 Analysts)
Q3 Income From Operations	Miss	-$14.69 mln	-$12.10 mln (7 Analysts)
Q3 Operating Expenses		$14.69 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Achieve Life Sciences Inc is $13.00, about 62.1% above its November 5 closing price of $4.93

Press Release: ID:nGNX9Y7NHV

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581060904"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581060904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581060904?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581060904","market":"fut","top_or_hot":-1,"title":"Achieve Life Sciences Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Achieve Q3 net loss and EPS missed analyst expectations</p></li><li><p>FDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026</p></li><li><p>Awarded FDA Commissioner's National Priority Voucher for vaping cessation</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company confirms PDUFA action date for cytisinicline as June 20, 2026</p></li><li><p>Achieve awarded FDA Priority Voucher for vaping cessation</p></li><li><p>Company highlights unmet need in vaping cessation market</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Total operating expenses for the three and nine months ended September 30, 2025, were $14.7 million and $40.1 million, respectively</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Miss</p></td><td><p>-$0.28</p></td><td><p>-$0.26 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$14.44 mln</p></td><td><p>-$12.20 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$14.69 mln</p></td><td><p>-$12.10 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$14.69 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Achieve Life Sciences Inc is $13.00, about 62.1% above its November 5 closing price of $4.93</p></li></ul><p>Press Release: <span>ID:nGNX9Y7NHV</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achieve Life Sciences Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchieve Life Sciences Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Achieve Q3 net loss and EPS missed analyst expectations</p></li><li><p>FDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026</p></li><li><p>Awarded FDA Commissioner's National Priority Voucher for vaping cessation</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company confirms PDUFA action date for cytisinicline as June 20, 2026</p></li><li><p>Achieve awarded FDA Priority Voucher for vaping cessation</p></li><li><p>Company highlights unmet need in vaping cessation market</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Total operating expenses for the three and nine months ended September 30, 2025, were $14.7 million and $40.1 million, respectively</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Miss</p></td><td><p>-$0.28</p></td><td><p>-$0.26 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$14.44 mln</p></td><td><p>-$12.20 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$14.69 mln</p></td><td><p>-$12.10 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$14.69 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Achieve Life Sciences Inc is $13.00, about 62.1% above its November 5 closing price of $4.93</p></li></ul><p>Press Release: <span>ID:nGNX9Y7NHV</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACHV","symbol_name":"Achieve Life Sciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0KW:1","article_id":"2581060904","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581060904","pubTimestamp":1762432313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Achieve Life Sciences Q3 net loss widensOverviewAchieve Q3 net loss and EPS missed analyst expectationsFDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026Awarded FDA ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACHV":"Achieve Life Sciences, Inc.","BK4139":"生物科技"},"translate_title":"实现生命科学第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHV":0.9},"content_text":"Achieve Life Sciences Q3 net loss widensOverviewAchieve Q3 net loss and EPS missed analyst expectationsFDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026Awarded FDA Commissioner's National Priority Voucher for vaping cessationOutlookCompany confirms PDUFA action date for cytisinicline as June 20, 2026Achieve awarded FDA Priority Voucher for vaping cessationCompany highlights unmet need in vaping cessation marketResult DriversTotal operating expenses for the three and nine months ended September 30, 2025, were $14.7 million and $40.1 million, respectivelyKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSMiss-$0.28-$0.26 (7 Analysts)Q3 Net IncomeMiss-$14.44 mln-$12.20 mln (7 Analysts)Q3 Income From OperationsMiss-$14.69 mln-$12.10 mln (7 Analysts)Q3 Operating Expenses$14.69 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Achieve Life Sciences Inc is $13.00, about 62.1% above its November 5 closing price of $4.93Press Release: ID:nGNX9Y7NHVFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}